glp-1 weight loss oral Wegovy Guide | Medical Denver & Greenwood Village US FDA accepts Novo Nordisk's

The objective of this review is to summarize the main renal outcomes from clinical studies while providing practical guidance on the use of GLP-1 RAs

2023;46(5):e117

doi: 10.1002/dmrr.3070 Summary Keywords GLP-1 receptor agonists, thyroid disorders, thyroid cancer, meta-analysis, randomized controlled trials Citation Hu W, Song R, Cheng R, Liu C, Guo R, Tang W, Zhang J, Zhao Q, Li X and Liu J (2022) Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials

Omzo's public-facing materials describe "third party networks of U.S.-licensed clinicians" but don't name the specific entity

Some have been serious, including vomiting, abdominal pain, and diarrhea

This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes